Choose smart money in health
4 reasons to raise funds with Angels Santé
Access our 150+ expert healthcare investors
Connect to our French and European healthcare ecosystem
Get active support throughout your business development
Connect to our French and European healthcare ecosystem
Become an exclusive member of the Angels Santé Family
How to be selected ?
- You are a French healthcare start-up (pas de Wellness , Foodtech).
- Votre équipe est si possible complémentaire (scientifique/business).
- Vous avez déjà levé en non dilutif ( quand le secteur le permet)
- Vous levez votre premier véritable tour de dilutif de minimum 400 K€
- Votre valo pré-money n'excéde pas les 5 m€.
- Your closing date is au moins 6 mois et votre cash burn permet de tenir 6 mois voire idéalement 12 mois .
- You have at least one POC (proof of concept).
- Depending on your sector
- Biotech : votre PoC est au stade pré-clinique invivo/résultats chez le petit animal
- Medtech : prototype fonctionnel avec essai probant
- Digital Health: votre solution est développée et présente un début de traction en B2B (commerciale, pilote, partenariat) ( traction démontrée pour les solutions B2C)
Tick all the boxes ?
Let's check your eligibility.
The Angels Santé fundraising process takes an average of 3 to 6 months from application to closing. Before applying, make sure you can anticipate this timeframe.
Our selection process
Submit your application on our Dealum platform
According to our investment thesis
A one-hour meeting before validation to pitch
/1 to 1.5 month
*210 € participation fee per company
( HR, IP, finance, contracts, négociation …)
1 month
pitch and investment
*4.5% Success fee
Discover our Portfolio Companies
AUSTRAL Dx is developing a new way to diagnose cardiac and pulmonary diseases to unclog ER dpt with airborne ultrasound.
an innovative start-up that is transforming the pharmaceutical industry by enabling pharmacies to manufacture personalised medicines using 3D printing
Sirius NeoSight is an innovative disruptive technology company for the detection of sub-clinical neo-cancers, relapses and the therapeutic follow-up of patients.
Primaa has developed an artificial intelligence capable of diagnosing different types of cancer based on biological samples taken from patients.
HuntX Pharma is developing small oral molecules to prevent the onset of genetic neurodegenerative diseases.
Hephaistos-Pharma is developing a new generation of immunostimulant to treat metastatic and hardly accessible tumors